CY-5

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameCY-5
Drug Alias NameCY-5
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChina Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesChina Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A